MCID: VGT001
MIFTS: 54

Vogt-Koyanagi-Harada Disease malady

Categories: Rare diseases, Neuronal diseases, Eye diseases, Immune diseases

Aliases & Classifications for Vogt-Koyanagi-Harada Disease

About this section
Sources:
11Disease Ontology, 46NIH Rare Diseases, 13DISEASES, 52Orphanet, 48Novoseek, 37MeSH, 66UMLS, 28ICD10, 30ICD9CM, 43NCIt, 29ICD10 via Orphanet, 60SNOMED-CT
See all MalaCards sources

Aliases & Descriptions for Vogt-Koyanagi-Harada Disease:

Name: Vogt-Koyanagi-Harada Disease 11 46 13 52 48
Uveomeningoencephalitic Syndrome 11 37 66
Uveomenigitic Syndrome 46 52
Vogt-Koyanagi-Harada Syndrome 46
 
Vogt-Koyanagi Syndrome 11
Harada's Disease 11
Vkh Syndrome 46
Vkh Disease 46

Characteristics:

Orphanet epidemiological data:

52
vogt-koyanagi-harada disease:
Inheritance: Multigenic/multifactorial; Age of onset: All ages; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology11 DOID:12297
ICD9CM30 363.22, 364.24
MeSH37 D014607
NCIt43 C85218
Orphanet52 ORPHA3437
ICD10 via Orphanet29 H20.8, H30.8

Summaries for Vogt-Koyanagi-Harada Disease

About this section
NIH Rare Diseases:46 Vogt-koyanagi-harada disease (vkh disease) is a condition that involves chronic inflammation of melanocytes, which are specialized cells that produce a pigment called melanin. melanin is the substance that gives skin, hair, and eyes their color. melanin is also found in the retina, where it plays a role in normal vision. people with vkh disease usually develop vision and hearing disturbances first, followed by signs of skin problems. the most common symptoms include headaches, panuveitis, vitiligo, hair loss (alopecia), and inner ear disturbances. neurological symptoms may also occur. the exact cause of vkh disease is not well understood, but research suggests it is an autoimmune disease. it is more common in people with darker skin pigmentation including asian, middle eastern, hispanic, and native american populations. the disease is treated with corticosteroids and other medications. last updated: 9/2/2016

MalaCards based summary: Vogt-Koyanagi-Harada Disease, also known as uveomeningoencephalitic syndrome, is related to panuveitis and sensorineural hearing loss, and has symptoms including sensorineural hearing impairment, abnormality of the eyelashes and visual impairment. An important gene associated with Vogt-Koyanagi-Harada Disease is PTPN22 (Protein Tyrosine Phosphatase, Non-Receptor Type 22), and among its related pathways are Rheumatoid arthritis and IL12-mediated signaling events. Affiliated tissues include eye, skin and retina, and related mouse phenotypes are immune system and hematopoietic system.

Disease Ontology:11 A hypersensitivity reaction type ii disease that is caused by t helper cell mediated autoimmune attack of melanocytes resulting in inflammation of the inside of the eye, whitening of hair, skin pigment loss, and meningitis.

Related Diseases for Vogt-Koyanagi-Harada Disease

About this section

Diseases related to Vogt-Koyanagi-Harada Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 144)
idRelated DiseaseScoreTop Affiliating Genes
1panuveitis31.1HLA-C, HLA-DRB1
2sensorineural hearing loss30.7HLA-A, HLA-B, HLA-DQB1, HLA-DRB1
3melanoma30.3IFNA2, TYR
4choroiditis11.0
5retinitis10.9
6wolffian duct adenocarcinoma10.7HLA-DQB1, HLA-DRB1
7quinquaud's decalvans folliculitis10.7HLA-DQB1, HLA-DRB1
8uveitis10.7
9parsonage turner syndrome10.7HLA-DQB1, HLA-DRB1
10common variable immunodeficiency10.7HLA-B, HLA-DRB1
11myopathy-growth delay-intellectual disability-hypospadias syndrome10.7HLA-DQB1, HLA-DRB1
12krieble bixler syndrome10.7HLA-DQB1, HLA-DRB1
13branch retinal artery occlusion10.7HLA-A, HLA-B
14malignant cardiac germ cell tumor10.7HLA-A, HLA-DQB1
15abdominal chemodectomas with cutaneous angiolipomas10.7HLA-DRB1, PTPN22
16limb dystonia10.7HLA-DQB1, HLA-DRB1
17spondylarthropathy10.7HLA-DQB1, HLA-DRB1
18hepatitis10.7
19hepatitis c10.7
20retinal detachment10.7
21rheumatic myocarditis10.6HLA-DQB1, HLA-DRB1
22epstein-barr virus hepatitis10.6HLA-B, HLA-DRB1
23headache10.6
24sympathetic ophthalmia10.6
25purpura fulminans10.6HLA-DQB1, HLA-DRB1
26autosomal recessive congenital methemoglobinemia10.5HLA-DRB1, NLRP1
27nephrosclerosis10.5HLA-A, HLA-DRB1, PTPN22
28scleritis10.5
29progressive locomotor ataxia10.5HLA-A, HLA-B, HLA-DRB1
30thrombotic thrombocytopenic purpura10.5HLA-A, HLA-B
31ascending cholangitis10.5HLA-B, HLA-C, HLA-DRB1
32hypercementosis10.5HLA-A, HLA-B, HLA-DRB1
33lymphocytic colitis10.5HLA-DQB1, HLA-DRB1
34intermittent proptosis10.5HLA-A, HLA-DRB1, PTPN22
35gonococcal iridocyclitis10.5HLA-A, HLA-B, HLA-C
36potato nose10.5HLA-A, HLA-B, HLA-DRB1
37vitreoretinochoroidopathy dominant10.5HLA-B, HLA-DQB1, HLA-DRB1
38ovarian papillary cystadenoma10.5HLA-B, HLA-DQB1, HLA-DRB1
39duodenal benign neoplasm10.5HLA-A, HLA-B, HLA-DRB1
40human herpesvirus 810.5HLA-A, HLA-B, HLA-C
41alopecia10.5
42lymphoma10.5
43posterior scleritis10.5
44neuropathy10.5
45acute posterior multifocal placoid pigment epitheliopathy10.5
46antigen-peptide-transporter 2 deficiency10.5HLA-A, HLA-B, PTPN22
47x-linked congenital generalized hypertrichosis10.5HLA-B, HLA-DQB1, HLA-DRB1
48conventional leiomyosarcoma10.5CD8A, HLA-DRB1
49nebulin-related early-onset distal myopathy10.5HLA-DQB1, HLA-DRB1, IL17A
50keratomalacia10.5HLA-B, HLA-C, HLA-DQB1

Graphical network of the top 20 diseases related to Vogt-Koyanagi-Harada Disease:



Diseases related to vogt-koyanagi-harada disease

Symptoms for Vogt-Koyanagi-Harada Disease

About this section

Symptoms:

 52 (show all 14)
  • abnormality of the eyelashes
  • glaucoma
  • visual impairment
  • cataract
  • abnormality of the eyebrow
  • retinal detachment
  • sensorineural hearing impairment
  • vitiligo
  • hypopigmented skin patches
  • sparse scalp hair
  • premature graying of hair
  • poliosis
  • short stature
  • cognitive impairment

HPO human phenotypes related to Vogt-Koyanagi-Harada Disease:

(show all 13)
id Description Frequency HPO Source Accession
1 sensorineural hearing impairment hallmark (90%) HP:0000407
2 abnormality of the eyelashes hallmark (90%) HP:0000499
3 visual impairment hallmark (90%) HP:0000505
4 hypopigmented skin patches hallmark (90%) HP:0001053
5 premature graying of hair hallmark (90%) HP:0002216
6 abnormal hair quantity hallmark (90%) HP:0011362
7 cognitive impairment hallmark (90%) HP:0100543
8 aplasia/hypoplasia of the eyebrow hallmark (90%) HP:0100840
9 glaucoma typical (50%) HP:0000501
10 visual impairment typical (50%) HP:0000505
11 cataract typical (50%) HP:0000518
12 retinal detachment typical (50%) HP:0000541
13 short stature typical (50%) HP:0004322

UMLS symptoms related to Vogt-Koyanagi-Harada Disease:


athetosis, discharge from eye

Drugs & Therapeutics for Vogt-Koyanagi-Harada Disease

About this section

Drugs for Vogt-Koyanagi-Harada Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 8)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
BevacizumabPhase 31938216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
2
Mycophenolic acid91924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
3
Povidone-iodine14425655-41-8
Synonyms:
 
Betadine
4
Mycophenolate mofetil919128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
5
Iodine5167553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
6
Azathioprine158446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
 
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
7cadexomer iodine484
8
Miconazole357322916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole

Interventional clinical trials:

idNameStatusNCT IDPhase
1Intravitreal Bevacizumab for Inflammatory Neovascular MembranesCompletedNCT00407121Phase 3
2Safety and Efficacy of AIN457 in Noninfectious UveitisCompletedNCT00685399Phase 2
3Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective StudyActive, not recruitingNCT02015351

Search NIH Clinical Center for Vogt-Koyanagi-Harada Disease


Cochrane evidence based reviews: uveomeningoencephalitic syndrome

Genetic Tests for Vogt-Koyanagi-Harada Disease

About this section

Anatomical Context for Vogt-Koyanagi-Harada Disease

About this section

MalaCards organs/tissues related to Vogt-Koyanagi-Harada Disease:

34
Eye, Skin, Retina, T cells, Ovary, Liver, Spinal cord

Animal Models for Vogt-Koyanagi-Harada Disease or affiliated genes

About this section

MGI Mouse Phenotypes related to Vogt-Koyanagi-Harada Disease:

39
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053877.7CD8A, FAS, HLA-DQB1, IL17A, NLRP1, PTPN22
2MP:00053977.4CD8A, FAS, HLA-DQB1, IL17A, NLRP1, PMEL

Publications for Vogt-Koyanagi-Harada Disease

About this section

Articles related to Vogt-Koyanagi-Harada Disease:

(show top 50)    (show all 347)
idTitleAuthorsYear
1
Relative changes in luminal and stromal areas of choroid determined by binarization of EDI-OCT images in eyes with Vogt-Koyanagi-Harada disease after treatment. (26847039)
2016
2
Choroidal Vascularity Index in Vogt-Koyanagi-Harada Disease: An EDI-OCT Derived Tool for Monitoring Disease Progression. (27525196)
2016
3
Optical Intensities of Different Compartments of Subretinal Fluid in Acute Vogt-Koyanagi-Harada Disease. (26871896)
2016
4
The Role of Optical Coherence Tomography Angiography in the Diagnosis and Management of Acute Vogt-Koyanagi-Harada Disease. (27440118)
2016
5
Choroidal circulation impairment during the anterior recurrence of Vogt-Koyanagi-Harada disease confirmed with indocyanine green angiography and laser speckle flowgraphy. (27079805)
2016
6
Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis. (27247899)
2016
7
Pseudotumoral and Multiple Retinal Pigment Epithelium Proliferation in Vogt-Koyanagi-Harada Disease. (26509089)
2015
8
Clinical Outcomes of Patients with Vogt-Koyanagi-Harada Disease Over 12 Years at a Tertiary Center. (26399962)
2015
9
Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. (25565265)
2015
10
Relationship between choroidal blood flow velocity and choroidal thickness during systemic corticosteroid therapy for Vogt-Koyanagi-Harada disease. (25619665)
2015
11
Association of HLA-DR4/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: A Systematic Review and Meta-analysis. (25382027)
2014
12
Decreased Interleukin-37 Expression in Vogt-Koyanagi-Harada Disease and Upregulation Following Immunosuppressive Treatment. (25343528)
2014
13
Cluster-like headache as presenting feature of Vogt-Koyanagi-Harada disease. (25591688)
2014
14
Vogt-Koyanagi-Harada disease in First Nations and MActis of Northern Alberta. (23769774)
2013
15
Retinal pigment epithelium folds as a diagnostic finding of Vogt-Koyanagi-Harada disease. (23149670)
2013
16
Vogt-Koyanagi-Harada disease masquerading as a lymphoproliferative process of the uvea. (23913248)
2013
17
Reversible alopecia in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. (23514340)
2013
18
Imaging in the diagnosis and management of Vogt-Koyanagi-Harada disease. (22954938)
2012
19
Resolution of subretinal fluid with systemic corticosteroid treatment in acute Vogt-Koyanagi-Harada disease. (22942161)
2012
20
Vogt-Koyanagi-Harada disease presenting as acute angle closure glaucoma at onset. (22452682)
2011
21
Intravitreal bevacizumab injection for persistent serous retinal detachment associated with Vogt-Koyanagi-Harada disease. (20689964)
2011
22
Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt--Koyanagi--Harada disease. (21251241)
2011
23
Choroidal evaluation using enhanced depth imaging spectral-domain optical coherence tomography in Vogt-Koyanagi-Harada disease. (21336069)
2011
24
Blue light and near-infrared fundus autofluorescence in acute Vogt-Koyanagi-Harada disease. (19965835)
2010
25
The prognostic value of angiography in Vogt-Koyanagi-Harada disease. (20933219)
2010
26
Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. (20036008)
2010
27
Vogt-Koyanagi-Harada disease: diagnosis and treatments update. (20829689)
2010
28
Magnetic resonance imaging of pachymeningeal enhancement in Vogt-Koyanagi-Harada disease. (20198496)
2010
29
Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection. (20177954)
2010
30
Presumed Vogt-Koyanagi-Harada disease with unilateral ocular involvement: report of three cases. (19308440)
2009
31
Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. (18834575)
2009
32
Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin? (18174263)
2008
33
Thunderclap headache as initial manifestation of Vogt-Koyanagi-Harada disease. (17868357)
2008
34
Characteristics of Vogt-Koyanagi-Harada disease in a French cohort: ethnicity, systemic manifestations, and HLA genotype data. (18379934)
2008
35
Vogt-Koyanagi-Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan. (17468832)
2007
36
IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. (17335887)
2007
37
Vogt-Koyanagi-Harada disease after head trauma. (17932867)
2007
38
Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. (16310490)
2005
39
Application of revised diagnostic criteria for vogt-koyanagi-harada disease in Japanese patients. (15838732)
2005
40
A case of Vogt-Koyanagi-Harada disease that developed relapsing polychondritis. (17029064)
2005
41
Prognostic factors for Vogt-Koyanagi-Harada disease. (12779034)
2003
42
Pathogenesis of Vogt-Koyanagi-Harada disease. (12189608)
2002
43
Bcl-2 expression by CD4 T lymphocytes in Vogt-Koyanagi-Harada disease. (12778345)
2002
44
Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. (11481264)
2001
45
Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. (9510558)
1998
46
Vitiligo in Vogt-Koyanagi-Harada disease: immunohistological analysis of inflammatory site. (8738701)
1996
47
Immunohistochemical studies of Vogt-Koyanagi-Harada disease with sunset sky fundus. (1974489)
1990
48
Retinal pigment epithelium disorder in Vogt-Koyanagi-Harada disease revealed by hyperosmolarity response of ocular standing potential. (6530837)
1984
49
Vitiligo with an inflammatory erythema in Vogt-Koyanagi-Harada disease: demonstration of filamentous masses and amyloid deposits. (7119218)
1982
50
The role of cytotoxic T lymphocytes in the pathogenesis of Vogt-Koyanagi-Harada disease. (6982444)
1982

Variations for Vogt-Koyanagi-Harada Disease

About this section

Expression for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section
Search GEO for disease gene expression data for Vogt-Koyanagi-Harada Disease.

Pathways for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section

Pathways related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 21)
idSuper pathwaysScoreTop Affiliating Genes
19.6HLA-DQB1, HLA-DRB1, IL17A
2
Show member pathways
9.6CD8A, HLA-A, HLA-DRB1
3
Show member pathways
9.6CD8A, HLA-A, HLA-DRB1
49.4CD8A, HLA-DQB1, HLA-DRB1, PTPN22
59.1HLA-A, HLA-B, HLA-C
69.1HLA-A, HLA-B, HLA-C
7
Show member pathways
9.1IL17A, TGFBR3, TLR3
88.7CD8A, HLA-A, HLA-B, HLA-C
9
Show member pathways
8.6HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
108.6HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
118.6HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
128.6HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
138.5CD8A, FAS, NLRP1, PTPN22, TLR3
14
Show member pathways
8.3FAS, HLA-A, HLA-B, HLA-C, IFNA2
15
Show member pathways
8.2HLA-A, HLA-B, HLA-C, IFNA2, IL17A
16
Show member pathways
8.2FAS, HLA-A, HLA-C, HLA-DQB1, TLR3
178.2CD8A, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
18
Show member pathways
8.0HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, IFNA2
19
Show member pathways
7.2FAS, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
20
Show member pathways
7.1CD8A, FAS, HLA-A, HLA-B, HLA-C, HLA-DQB1
21
Show member pathways
6.2CD8A, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1

GO Terms for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section

Cellular components related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1MHC class II protein complexGO:004261310.5HLA-DQB1, HLA-DRB1
2melanosome membraneGO:003316210.3TYR, TYRP1
3clathrin-coated endocytic vesicle membraneGO:003066910.1HLA-DQB1, HLA-DRB1, TYRP1
4MHC class I protein complexGO:00426129.7HLA-A, HLA-B, HLA-C
5melanosomeGO:00424709.4PMEL, TYR, TYRP1
6external side of plasma membraneGO:00098979.4CD8A, FAS, IL17A, TGFBR3
7early endosome membraneGO:00319019.3HLA-A, HLA-B, HLA-C
8phagocytic vesicle membraneGO:00306709.3HLA-A, HLA-B, HLA-C
9integral component of lumenal side of endoplasmic reticulum membraneGO:00715569.1HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
10ER to Golgi transport vesicle membraneGO:00125079.1HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
11Golgi membraneGO:00001398.1HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, TLR3
12cell surfaceGO:00099867.2CD8A, FAS, HLA-A, HLA-B, HLA-C, HLA-DRB1

Biological processes related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1melanosome organizationGO:003243810.3PMEL, TYRP1
2necroptotic signaling pathwayGO:009752710.2FAS, TLR3
3antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independentGO:00024809.7HLA-A, HLA-B, HLA-C
4melanin biosynthetic processGO:00424389.7PMEL, TYR, TYRP1
5antigen processing and presentation of peptide antigen via MHC class IGO:00024749.7HLA-A, HLA-B, HLA-C
6antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentGO:00024799.5HLA-A, HLA-B, HLA-C
7type I interferon signaling pathwayGO:00603379.2HLA-A, HLA-B, HLA-C, IFNA2
8antigen processing and presentationGO:00198829.1CD8A, HLA-A, HLA-B, HLA-C
9interferon-gamma-mediated signaling pathwayGO:00603339.1HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
10regulation of immune responseGO:00507768.9CD8A, HLA-A, HLA-B, HLA-C
11immune responseGO:00069558.8CD8A, FAS, HLA-DQB1, IL17A, TGFBR3
12inflammatory responseGO:00069547.9FAS, IFNA2, IL17A, NLRP1, TLR3

Molecular functions related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1peptide antigen bindingGO:00426058.6HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1

Sources for Vogt-Koyanagi-Harada Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet